In view of the markedly protective roles that FXR signal pathway and FGF19 play in GSD [39], NAFLD impairing this pathway may account for the increasing incidence of GSD complications. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatotic liver disease.